BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) on Tuesday agreed to acquire Astria Therapeutics, Inc. ( NASDAQ:ATXS ) for a mix of cash and stock. The deal represents an implied value of $13 per Astria share, and approximately $700 million in enterprise value.

ATXS

BioCryst制藥

<p>BioCryst Pharmaceuticals, Inc.（納斯達克代碼：BCRX）週二同意以現金和股票的組合收購 Astria Therapeutics, Inc.（納斯達克代碼：ATXS）。該交易對 Astria 每股的隱含價值為 13 美元，企業價值約為 7 億美元</p>

為什麼 BioCryst 製藥的股票今天下跌？